Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors.

Linked as:


Document options

Extract

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors.

No longer available (Autolink)

See the full content of this document